• Administration/Government
  • Agronomy/Food Science
  • Architecture
  • Arts and Design
  • Astronomy
  • Business/Economics
  • Careers/Employment
  • Chemistry
  • Civil Engineering/Traffic Engineering
  • Computer Science/Telecom
  • Earth Sciences
  • Education/Continuing Education
  • Environmental Sciences
  • Event
  • History/Archeology
  • Interdisciplinary/All Categories
  • Law/Forensics
  • Life Sciences
  • Literature/Linguistics
  • Mathematics
  • Mechanical Engineering/Mechanics
  • Media Sciences/Political Sciences
  • Medicine/Pharmacology
  • Microtechnics/Electroengineering
  • Pedagogy/Education Science
  • Philosophy
  • Physics/Materials Science
  • Psychology
  • Social Sciences
  • Sport Sciences
  • Study of Religions
  • Veterinary Science



Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone 20mg
Glatopa is the first FDA-approved, substitutable generic version of Copaxone 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full r
Medicine/Pharmacology - Administration/Government
Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States
US Food and Drug Administration (FDA) grants approval of the AcrySof IQ ReSTOR +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the correct
Medicine/Pharmacology - Life Sciences
Data in The Lancet show Novartis drug Arzerra plus chlorambucil improved median progression-free survival by 71% in CLL patients
Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in Western countries, accounting for approximately 1 in 4 cases of all leukemia , 75% of CLL patients are over 65 years of age at time of diagnosis and majority have at least one comorbidity suc
Medicine/Pharmacology - Life Sciences
Gilenya data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians
New analysis will confirm high efficacy of Gilenya in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding brain shrinkage to an existing assessment tool enhances ability to predict disability progression in relapsing MS (RMS) Early data on a novel method to assess motor function in patients with MS and its potential clinical application will also be
Medicine/Pharmacology - Administration/Government
Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload
Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment administra
Medicine/Pharmacology - Life Sciences
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances th
Medicine/Pharmacology - Life Sciences
Novartis’ Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients
After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response New data at AAD shows 7 out of 10 psoriasis patients, who were PASI 75 responders at 52 Weeks, had almost clear to clear skin (PASI 90 to PASI 100) after two years of Cosentyx 300 mg treatment Cosentyx is the first and only IL-17A inhibitor approved in Europe, the US, Japan, Canada and Switzerland for moderate
Medicine/Pharmacology - Life Sciences
New Novartis data shows Cosentyx(TM) is significantly superior to Stelara and clears skin (PASI 90) in nearly 80% of psoriasis patients
CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx (TM) compared to Stelara at Week 16 Cosentyx showed greater improvements to Stelara across all study endpoints up to Week 16, including PASI 100 and onset of action PASI 90 and PASI 100 are both considered important measures of treatment success for psoriasis patients, demonstrating clear to almost clear skin ,
Medicine/Pharmacology - Life Sciences
Novartis receives EU approval for Jakavi in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer
Jakavi (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with an o
Medicine/Pharmacology - Life Sciences
Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin
Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara in clearing skin (PASI 90 and PASI 100) New data from the long-term Phase III program to be presented demonstrating Cosentyx efficacy and safety over two years in psoriasis patients Cosentyx is the first and only IL-17A inhibitor approved in Europe, the US, Japan Canada and Switzerland for moderate-to-severe plaque psoriasis[2-4]
Medicine/Pharmacology - Life Sciences
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the
Medicine/Pharmacology - Business/Economics
Novartis announces completion of transactions with GSK
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company
Positive phase II data highlights benefits of Alcon’s RTH258 for patients with neovascular (wet) age-related macular degeneration
Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less frequent
Medicine/Pharmacology - Life Sciences
Novartis lung cancer drug Zykadia recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib
If approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the A
Business/Economics - Medicine/Pharmacology
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Shareholders approve 18 th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors
Medicine/Pharmacology - Life Sciences
Novartis receives FDA approval of Farydak , the first HDAC inhibitor for patients with multiple myeloma
Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD Farydak prolonged median
Novartis’ heart failure medicine LCZ696 granted FDA priority review
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Nearly six million people live with heart failure in the US, and despite curre
Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief
US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post
Novartis announces study in NEJM showing Jakavi was superior to standard therapy in rare blood cancer polycythemia vera
Jakavi (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera Polycythemia vera (PV)
Business/Economics - Medicine/Pharmacology
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Net sales grew in FY 2014, with strong core margin expansion Net sales increased 1% (+3% cc ) to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7 billion
Novartis Bexsero vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexib
Novartis drug Jakavi recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack Clinical data show Jakavi (ruxol
Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients
Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A , Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis Approval based on the efficacy and safety outcomes from 10 Phase II and III studies which included over 3,990 adult patients with mo
Medicine/Pharmacology - Life Sciences
Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients
Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects ; all other biologics are recommended for second-line therapy[2-4] Cosentyx showed superiority to Stelara in the Phase IIIb CLEAR study In Phase III studies, 70% or more Cosentyx 300 mg patients achieved clear skin (PASI 100) or almost clear sk
Medicine/Pharmacology - Computer Science/Telecom
Novartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patients
Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with technolo
Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA
P ivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant im
Medicine/Pharmacology - Business/Economics
Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee
Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested i
Medicine/Pharmacology - Life Sciences
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology
Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for using CRISPR to engineer chimeric antigen receptor T-cells and hematopoietic stem cells Basel, Switzerland, January 7, 2015 - Novartis announced today that it has signed collaboration and licensing agreements with Intellia Therapeutics for th
Medicine/Pharmacology - Business/Economics
Novartis completes divestment of Animal Health business to Eli Lilly for USD 5.4 billion
Novartis announced today that it has completed effective January 1, 2015 the divestment of its Animal Health Division to Eli Lilly and Company (Lilly) for approximately USD 5.4 billion.
Medicine/Pharmacology - Life Sciences
First in the world regulatory approval of Novartis’ Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis
Novartis Global select country select business Cosentyx (secukinumab) approval is based on Phase III program demonstrating high, sustained efficacy in the skin clearance of moderate-to-severe plaque psoriasis and improvement of signs and symptoms of psoriatic arthritis[1-5] Many patients do not respond to or tolerate current psoriasis or psoriatic arthritis treatments, indicating an unmet need for new therapies for these d
Medicine/Pharmacology - Business/Economics
Alcon treatment Travatan receives EU approval for pediatric glaucoma patients
Novartis Global select country select business New indication to decrease elevated intraocular pressure in patients, aged two months to less than 18 years, with ocular hypertension
Medicine/Pharmacology - Chemistry
Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis Global select country select business Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels
Medicine/Pharmacology - Life Sciences
Novartis announces results of trial evaluating the use of Afinitor in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis Global select country select business BOLERO-1 trial explored everolimus in women with HER2+ advanced breast cancer and did not meet criteria for statistical significance
Medicine/Pharmacology - Life Sciences
Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara in clearing skin
Novartis Global select country select business Cosentyx showed superiority to Stelara ; meeting the primary endpoint of achieving PASI 90, which represents clear or almost clear skin at Week 16 and secondary endpoint of achieving PASI 75 at Week 4 for psoriasis patients CLEAR is the second head-to-head study for Cosentyx following the Phase III FIXTURE study that showed Cosentyx was superior to Enbrel (etanercept)
Medicine/Pharmacology - Chemistry
Six-year pivotal study data reinforce the superiority of Tasigna over Glivec in newly-diagnosed patients with Ph+ CML
Fewer patients on Tasigna vs.
Medicine/Pharmacology - Social Sciences
Novartis announces safety and efficacy benefit of Jakavi in global clinical trial of over 1,000 patients with myelofibrosis
Data from ongoing trial reinforces the safety profile of Jakavi (ruxolitinib) as seen in previous Phase III studies Patients on Jakavi experienced a reduction in spleen size that was mainta
Medicine/Pharmacology - Physics/Materials Science
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN
Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in the US The abstract of the study results is published online as part of the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Holzkirchen, December 8, 2014 - Sandoz, a Novartis company, announced today Phase I
Medicine/Pharmacology - Life Sciences
Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions Additionally, sustained remissions were achieved up to one year or more with 6-month event-free survival of 70% and overall survival of 75%, in most cases without further therapy Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR'T cell therapie
Medicine/Pharmacology - Life Sciences
Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia Studies targeting multiple cancer pathways in rare blood ca
Medicine/Pharmacology - Life Sciences
Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)
PPMS is distinct from other types of MS, with no approved treatment that can change the course of this devastating disease Novartis remains strongly committed to identifying and developing treatment options for patients with chronic debilitating neurological conditions Basel, Dec 1, 2014 - Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures.
Novartis’ heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]
LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening the formal review clock by 60 days Approximately 15 million people in the EU live with
Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589
Basel , November 25, 2014 - Novartis announced today that the US Food and Drug Administration (FDA) has extended their priority review period by up to three months for the new drug application (ND
Novartis drug Signifor approved in EU, marking an advance for patients with inadequately controlled acromegaly
Acromegaly is a rare pituitary disorder, which requires normalization of hormonal levels to help prevent the serious consequences of the disease , , , Approval based on two large phase III
Medicine/Pharmacology - Life Sciences
Novartis Cosentyx(TM) receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients
Cosentyx (secukinumab, formerly AIN457) is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe In Phase III stud
Medicine/Pharmacology - Environmental Sciences
Novartis Foundation symposium showcases sustainable healthcare interventions
Event illustrates how strong partnerships and innovative service delivery models can result in improved patient outcomes in lowand middle-income countries Selected interventions demonstrate success in moving past the pilot phase towards validation and scale, including a telemedicine project that aims to improve healthcare access in rural areas of Ghana The Novartis Foundation strategic approach to philanthropy includes partnerships,
Nine new analyses show Novartis’ LCZ696 could change course of heart failure for patients[1],[2]
New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril Patients' and doctors' assessments of disease severity were also significantly better with LCZ696 than enalapril Effects on certain heart biomarkers indicate that compared to enalapril, LCZ696 reduced cardiac stress and damage
Novartis reports landmark Phase III results for AIN457 (secukinumab) showing rapid and significant efficacy in psoriatic arthritis patients
Secukinumab demonstrated significant and sustained efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA) in two pivotal studies - FUTURE 1 and FUTURE 2 are the first Phase III studies of a selective IL-17A inhibitor in PsA, a painful, debilitating condition causing inflammation of joints and skin , In FUTURE 1 more than 80% of secukinumab-treated patients experienced no progression of joi
Medicine/Pharmacology - Life Sciences
Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
More than 60% of secukinumab 150 mg patients achieved significant improvements in AS symptoms, seen as early as Week 1 and sustained through one year of treatment , Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies , Up to 40% of AS patients have inadequate or no response to standard of care anti-TNF (tumor-necrosis-facto
Medicine/Pharmacology - Business/Economics
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria Novartis associates rallied behind Power of One
Medicine/Pharmacology - Physics/Materials Science
Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Detailed results of four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor with Phase III data to demonstrate efficacy and improve symptoms in patients with PsA and AS Data will include study results from FUTURE 1 and FUTURE 2 in PsA and MEASURE 1 and MEASURE 2 in AS;
Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589
Committee votes against recommending LBH589 plus bortezomib and dexamethasone for patients with previously treated multiple myeloma LBH589 has the potential to be an important treatment optio
Business/Economics - Medicine/Pharmacology
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter
Net sales up 4% (+5% cc) in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc ) in Q3 Strong operating income growth in Q3 of 14% (+18% cc) Core
Medicine/Pharmacology - Business/Economics
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influen
Medicine/Pharmacology - Life Sciences
Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Secukinumab is the first selective IL-17A inhibitor to meet primary endpoint in two pivotal Phase III studies showing improvement in active ankylosing spondylitis (AS) patients' symptoms versus placebo AS is a painful, progressively debilitating condition associated with inflammation of the spine, causing irreversible consequences that significantly reduce patients' mobility and quality of life , Up to 40% of patients have an
Copyright © Apr 2015, Scimetrica. All Rights Reserved.